Financial Summary

Mesoblast Limited  (MESO)  $14.93    (%)

  • Symbol
    MESO
    Price
    14.93$
    Beta
    1.610619
    Volume Avrg.
    602669
    Market Cap
    1753095550
    Last Div
    0
    Range
    3.12-21.28
    Changes
    -0.35
    Changes Percentage
    Exchange
    Nasdaq Global Select
    Industry
    Biotechnology
    Ceo
    Dr. Silviu Itescu
    Sector
    Healthcare

About company

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and GrĂ¼nenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.


Income Statement

YearRevenueCost of revenuesGross profitOperating expensessOperating incomesInterest expenseIncome tax expensesEarnings before taxsNet incomeEarnings per share basicsEarnings per share dilutedsDividend per sharesGross marginsEBIT marginsProfit marginsEBITDAEBITEarnings Before Tax MarginsNet Profit Margins
2020220747.00 151286.00 104956.00 38668.0066288.002873.00968.0067091.0057411.003.308587268217793.280.8033334143460.4754583301250.3002894716580.26007601462377344.0066288.000.3039271201870.260076014623
2019260174.00 161782.00 98392.00 34462.006393.003576.0010481.0065737.0055256.0011.9711.893.037054038220.378177681090.2457201718850.2123809450676477.006393.000.2526655238420.21238094506
2018265595.00 163756.00 101839.00 30941.0070898.00324.0013372.0072903.0059531.0012.0111.912.742340216980.38343718820.2669402661950.22414202074681801.0070898.000.2744893540920.224142020746
2017229234.00 141048.00 88186.00 26842.0061344.002323.0015738.0064089.0048351.009.279.212.431406868490.3846986049190.2676042820870.21092420845171501.0061344.000.2795789455320.210924208451
2016215639.00 131376.00 84263.00 24239.0060024.001456.0015685.0061372.0045687.008.358.312.208978050390.3907595564810.2783541010670.21186798306470529.0060024.000.2846052893960.211867983064
2015233715.00 140089.00 93626.00 22396.007123.00733.0019121.0072515.0053394.009.289.221.995660676580.4005990201740.3047729071730.22845773698782487.007123.000.3102710566290.228457736987
2014182795.00 112258.00 70537.00 18034.0052503.00384.0013973.0053483.003951.006.496.451.8171831440.3858803577780.2872233923250.21614376760960449.0052503.000.2925845892940.216143767609
201317091.00 106606.00 64304.00 15305.0048999.00136.0013118.0050155.0037037.0040.0339.7511.3388761160.3762448072080.2866947516240.21670469837955756.0048999.000.2934585454330.216704698379
2012156508.00 87846.00 68662.00 13421.0055241.000.001403.0055763.0041733.0044.6444.152.631815561350.4387123980880.352959593120.26665090602458518.0055241.000.3562948858840.266650906024
2011108249.00 64431.00 43818.00 10028.003379.000.008283.0034205.0025922.0028.0527.680.00.4047889587890.3121506896140.23946641539435604.003379.000.3159844432740.239466415394
201065225.00 39541.00 25684.00 7299.0018385.000.004527.001854.0014013.0015.4115.150.00.3937753928710.2818704484480.21484093522419412.0018385.000.2842468378690.214840935224
200942905.00 25683.00 17222.00 5482.001174.000.003831.0012066.008235.001.3171.2970.00.40140.28120.192128.0012066.000.28120.1919
Year202020192018201720162015201420132012201120102009
Revenue220747.00260174.00265595.00229234.00215639.00233715.00182795.0017091.00156508.00108249.0065225.0042905.00
Cost of revenues151286.00161782.00163756.00141048.00131376.00140089.00112258.00106606.0087846.0064431.0039541.0025683.00
Gross profit 104956.00 98392.00 101839.00 88186.00 84263.00 93626.00 70537.00 64304.00 68662.00 43818.00 25684.00 17222.00
Operating expensess38668.0034462.0030941.0026842.0024239.0022396.0018034.0015305.0013421.0010028.007299.005482.00
Operating incomes66288.006393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.001174.00
Interest expense2873.003576.00324.002323.001456.00733.00384.00136.000.000.000.000.00
Income tax expenses968.0010481.0013372.0015738.0015685.0019121.0013973.0013118.001403.008283.004527.003831.00
Earnings before taxs67091.0065737.0072903.0064089.0061372.0072515.0053483.0050155.0055763.0034205.001854.0012066.00
Net income57411.0055256.0059531.0048351.0045687.0053394.003951.0037037.0041733.0025922.0014013.008235.00
Earnings per share basics3.3085872682177911.9712.019.278.359.286.4940.0344.6428.0515.411.317
Earnings per share diluteds3.2811.8911.919.218.319.226.4539.7544.1527.6815.151.297
Dividend per shares0.83.042.742.432.2121.8211.342.63000
Gross margins0.480.380.380.380.390.40.390.380.440.40.390.4
EBIT margins0.30.250.270.270.280.30.290.290.350.310.280.28
Profit margins0.260.210.220.210.210.230.220.220.270.240.210.19
EBITDA77344.0076477.0081801.0071501.0070529.0082487.0060449.0055756.0058518.0035604.0019412.00128.00
EBIT66288.006393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.0012066.00
Earnings Before Tax Margins0.30.250.270.280.280.310.290.290.360.320.280.28
Net Profit Margins0.260.210.220.210.210.230.220.220.270.240.210.19